Health & Medical · Week of Nov 2, 2026
CVS Health plans split as diagnostics firms report: health week
Earnings from Caris and GRAIL, a planned CVS Health split, board and capital moves, and a Medtronic-MJFF education effort on deep brain stimulation.
Corporate structure and financial results dominated the week's health releases. CVS Health said it intends to separate into two publicly traded companies, one built around Aetna, CVS Caremark and Oak Street Health and the other around roughly 9,000 CVS pharmacies, with completion expected in the first half of 2028. Elsewhere, DarioHealth named John R. Palumbo chairman, and Accuray announced a 1-for-40 reverse stock split that it says is meant to help it regain compliance with Nasdaq's minimum bid price requirement.
In diagnostics, two cancer-testing companies reported third-quarter 2026 results on Nov. 4. Caris Life Sciences reported 27% revenue growth and raised its full-year guidance. GRAIL reported a net loss of $103.6 million and said it anticipates an FDA decision on its Galleri test by early Q1 2027. Medtronic and The Michael J. Fox Foundation launched patient education resources on deep brain stimulation, and Elanco Animal Health released survey data on U.S. pet health spending.
Caris Life Sciences
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Caris Life Sciences reported third-quarter 2026 revenue of $275.4 million, up 27% year over year, and net income of $15.3 million, and raised full-year 2026 revenue guidance to $1.04 to $1.05 billion. The company says growth came mainly from higher clinical case volume, about 61,500 cases, and average selling price improvements, while gross margin fell to 66% from 68% and free cash flow was $(39.7) million.
GRAIL, Inc.
GRAIL Reports Third Quarter 2026 Financial Results
GRAIL reported third-quarter 2026 total revenue of $37.5 million, with Galleri test revenue up 14% to $37.3 million, and a net loss of $103.6 million. The company says an FDA advisory panel voted in favor of approving Galleri in September and that it anticipates an FDA decision by early Q1 2027, with $788.7 million in cash and short-term securities as of September 30, 2026.
CVS Health
CVS Health Announces Intent to Create Two Distinct Leaders in Healthcare
CVS Health says it intends to separate into two independent public companies: a healthcare solutions company with Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health, led by David Joyner, and CVS Pharmacy, led by Prem Shah. The company expects to complete the separation in the first half of 2028, subject to conditions including final board approval and confirmation of tax-free treatment, and says both companies are expected to have a solid investment grade rating and pay a dividend.
DarioHealth Corp.
Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care
DarioHealth appointed board member John R. Palumbo as Chairman effective November 3, 2026, succeeding Yoav Shaked, who will remain a director. The company says the change comes as consumer-directed and payer-funded care converge, and Palumbo will join its November 12, 2026 earnings call to discuss strategic priorities.
Medtronic plc
Medtronic and Michael J. Fox Foundation Partner to Help More People with Parkinson's Understand Deep Brain Stimulation
Medtronic and The Michael J. Fox Foundation announced an educational initiative on deep brain stimulation for people with Parkinson's and their caregivers, with resources available at michaeljfox.org/dbs. Medtronic is the premier partner and funds the materials, while MJFF says it maintains editorial oversight.
The Michael J. Fox Foundation for Parkinson's Research; Medtronic
Michael J. Fox Foundation and Medtronic Partner to Help More People with Parkinson's Understand Deep Brain Stimulation
In a companion release, MJFF described the same DBS initiative, including "The Live On with DBS Education Hub," a practical guide and an interactive webinar covering benefits, risks, surgery preparation and life with a device. MJFF says it has funded more than $29 million in DBS research for Parkinson's since 2000.
Accuray Incorporated
Accuray Announces 1-for-40 Reverse Stock Split
Accuray's board approved a 1-for-40 reverse stock split effective 12:02 a.m. Eastern Time on November 9, 2026. The split reduces outstanding shares from about 120.2 million to about 3.0 million, and the company says it is intended to help regain compliance with Nasdaq's minimum bid price requirement.
Elanco Animal Health
October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority
Elanco Animal Health released an October 2026 survey of 2,018 U.S. adults in which 93% of pet owners said they maintained or increased pet spending and 7% of consumers said they would cut pet health spending under economic pressure. The survey, commissioned by Elanco, also found 38% of pet owners have shifted medication purchasing outside the clinic in the past year or two.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Prime News Global reporting.